Processa Pharmaceuticals, Inc. Lease, Cost
Processa Pharmaceuticals, Inc. (PCSA) reported Lease, Cost of $22.46 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2025-08-07
- Processa Pharmaceuticals, Inc. lease, cost for the quarter ending 2025-06-30 was $22.46K, a 0.00% change year-over-year.
- Processa Pharmaceuticals, Inc. lease, cost for the quarter ending 2025-03-31 was $22.46K, a 0.00% change year-over-year.
- Processa Pharmaceuticals, Inc. lease, cost for the quarter ending 2024-12-31 was $22.00K, a 8.33% decline year-over-year.
- Processa Pharmaceuticals, Inc. lease, cost for the quarter ending 2024-09-30 was $23.00K, a 4.17% decline year-over-year.
- Processa Pharmaceuticals, Inc. lease, cost for fiscal 2024 was $90.00K, a 7.22% decline from fiscal 2023.
- Processa Pharmaceuticals, Inc. lease, cost for fiscal 2023 was $97.00K, a 0.00% change from fiscal 2022.
- Processa Pharmaceuticals, Inc. lease, cost for fiscal 2022 was $97.00K, a 2.90% increase from fiscal 2021.
- Processa Pharmaceuticals, Inc. lease, cost for fiscal 2021 was $94.26K, a 3.36% decline from fiscal 2020.
| Period end | Lease, Cost 3 month | Lease, Cost 3 month as first filed | Lease, Cost 6 month | Lease, Cost 6 month as first filed | Lease, Cost 9 month | Lease, Cost 9 month as first filed | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | $22.46K 10-Q · filed 2025-08-07 | $44.92K 10-Q · filed 2025-08-07 | $66.92K derived: sum of 3 quarters · filed 2025-08-07 | $89.92K derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2025-03-31 | $22.46K 10-Q · filed 2025-05-08 | $44.46K derived: sum of 2 quarters · filed 2025-05-08 | $67.46K derived: sum of 3 quarters · filed 2025-05-08 | $89.92K derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $45.00K derived: sum of 2 quarters · filed 2025-03-20 | $67.46K derived: sum of 3 quarters · filed 2025-08-07 | $90.00K 10-K · filed 2025-03-20 | ||||
| 2024-09-30 | $23.00K 10-Q · filed 2024-10-30 | $45.46K derived: sum of 2 quarters · filed 2025-08-07 | $68.00K 10-Q · filed 2024-10-30 | $91.92K derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-06-30 | $22.46K 10-Q · filed 2025-08-07 | $23.00K 10-Q · filed 2024-08-13 | $44.92K 10-Q · filed 2025-08-07 | $45.00K 10-Q · filed 2024-08-13 | $68.92K derived: sum of 3 quarters · filed 2025-08-07 | $92.92K derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $22.46K 10-Q · filed 2025-05-08 | $46.46K derived: sum of 2 quarters · filed 2025-05-08 | $70.46K derived: sum of 3 quarters · filed 2025-05-08 | $94.46K derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $48.00K derived: sum of 2 quarters · filed 2025-03-20 | $72.00K derived: sum of 3 quarters · filed 2025-03-20 | $97.00K 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $24.00K 10-Q · filed 2024-10-30 | $48.00K derived: sum of 2 quarters · filed 2024-10-30 | $73.00K 10-Q · filed 2024-10-30 | $94.46K derived: sum of 4 quarters · filed 2024-10-30 | ||||
| 2023-06-30 | $24.00K 10-Q · filed 2024-08-13 | $49.00K 10-Q · filed 2024-08-13 | $70.46K derived: sum of 3 quarters · filed 2024-08-13 | $94.46K derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $22.46K 10-Q · filed 2024-05-10 | $46.46K derived: sum of 2 quarters · filed 2024-05-10 | $70.46K derived: sum of 3 quarters · filed 2024-05-10 | $94.46K derived: sum of 4 quarters · filed 2024-05-10 | ||||
| 2022-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $48.00K derived: sum of 2 quarters · filed 2024-03-29 | $72.00K derived: sum of 3 quarters · filed 2024-03-29 | $97.00K 10-K · filed 2024-03-29 | $96.78K 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $24.00K 10-Q · filed 2023-11-13 | $23.68K 10-Q · filed 2022-11-08 | $48.00K derived: sum of 2 quarters · filed 2023-11-13 | $73.00K 10-Q · filed 2023-11-13 | $72.21K 10-Q · filed 2022-11-08 | $94.15K derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $24.00K 10-Q · filed 2023-08-10 | $24.14K 10-Q · filed 2022-08-11 | $49.00K 10-Q · filed 2023-08-10 | $48.53K 10-Q · filed 2022-08-11 | $70.15K derived: sum of 3 quarters · filed 2023-08-10 | $94.35K derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $21.92K 10-Q · filed 2023-05-15 | $24.39K 10-Q · filed 2022-05-12 | $46.15K derived: sum of 2 quarters · filed 2023-05-15 | $70.35K derived: sum of 3 quarters · filed 2023-05-15 | $92.15K derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $24.23K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $48.43K derived: sum of 2 quarters · filed 2023-03-30 | $70.23K derived: sum of 3 quarters · filed 2023-03-30 | $94.26K 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $24.20K 10-Q · filed 2022-11-08 | $46.00K derived: sum of 2 quarters · filed 2022-11-08 | $70.03K 10-Q · filed 2022-11-08 | $95.34K derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $21.80K 10-Q · filed 2022-08-11 | $45.83K 10-Q · filed 2022-08-11 | $71.15K derived: sum of 3 quarters · filed 2022-08-11 | $95.17K derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $24.03K 10-Q · filed 2022-05-12 | $49.34K derived: sum of 2 quarters · filed 2022-05-12 | $73.37K derived: sum of 3 quarters · filed 2022-05-12 | $97.37K derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $25.32K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $49.34K derived: sum of 2 quarters · filed 2022-03-30 | $73.34K derived: sum of 3 quarters · filed 2022-03-30 | $97.55K 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | $24.03K 10-Q · filed 2021-11-12 | $48.02K derived: sum of 2 quarters · filed 2021-11-12 | $72.23K 10-Q · filed 2021-11-12 | $96.63K derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | $24.00K 10-Q · filed 2021-08-12 | $48.20K 10-Q · filed 2021-08-12 | $72.60K derived: sum of 3 quarters · filed 2021-08-12 | $96.92K derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $24.21K 10-Q · filed 2021-05-13 | $48.61K derived: sum of 2 quarters · filed 2021-05-13 | $72.92K derived: sum of 3 quarters · filed 2021-05-13 | $97.65K derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | $24.40K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $48.72K derived: sum of 2 quarters · filed 2021-03-25 | $73.45K derived: sum of 3 quarters · filed 2021-03-25 | $98.02K 10-K · filed 2021-03-25 | ||||
| 2019-09-30 | $24.32K 10-Q · filed 2020-11-12 | $49.05K derived: sum of 2 quarters · filed 2020-11-12 | $73.62K 10-Q · filed 2020-11-12 | $95.15K derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | $24.73K 10-Q · filed 2020-08-05 | $49.30K 10-Q · filed 2020-08-05 | $70.83K derived: sum of 3 quarters · filed 2020-08-05 | $84.24K derived: sum of 4 quarters · filed 2020-08-05 | ||||
| 2019-03-31 | $24.57K 10-Q · filed 2020-05-15 | $24.56K 10-Q · filed 2019-05-14 | $46.10K derived: sum of 2 quarters · filed 2020-05-15 | $59.51K derived: sum of 3 quarters · filed 2020-05-15 | $84.83K derived: sum of 4 quarters · filed 2020-05-15 | |||
| 2018-12-31 | $21.52K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | $34.94K derived: sum of 2 quarters · filed 2020-03-06 | $60.26K derived: sum of 3 quarters · filed 2020-03-06 | $88.24K 10-K · filed 2020-03-06 | ||||
| 2018-09-30 | $13.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $38.73K derived: sum of 2 quarters · filed 2019-11-14 | $66.71K 10-Q · filed 2019-11-14 | |||||
| 2018-06-30 | $25.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $53.30K 10-Q · filed 2019-08-14 | ||||||
| 2018-03-31 | $27.98K 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |